Possibility and prospects for the use of recombinant neutralizing monoclonal antibodies (bamlanivimab+etesevimab, sotrovimab) in patients with COVID-19


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Currently, there are prerequisites, such as data from phase 2 and 3 multicenter clinical trials, to recommend sotrovimab and bamlanivimab+etesevimab at the prehospital stage for outpatients positive for COVID-19 and in the first 10 days of symptom onset. Further research and long-term data from ongoing studies are required to confirm or disprove the initial results and understand how the emergence of new variants of viruses may affect the effectiveness of monoclonal antibodies that neutralize SARS-CoV-2.

Texto integral

Acesso é fechado

Sobre autores

Vitaly Tsvetov

Federal Center for Cardiovascular Surgery

Cand. Sci. (Med.), Clinical Pharmacologist Chelyabinsk, Russia

I. Burashnikova

Kazan State Medical Academy - Branch Campus of the Russian Medical Academy of Continuous Professional Education

Kazan, Russia

D. Sychev

Russian Medical Academy of Continuous Professional Education

Moscow, Russia

Bibliografia

  1. Cochrane Database of Systematic Reviews. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Version published: 02 September 2021. doi: 10.1002/14651858. CD013825.pub2.
  2. Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19) 13-е изд., Москва: Министерство здравоохранения Российской Федерации, 2021. 231 c.
  3. Pinto D., Park YJ., Beltramello M., et al. neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290-95. doi: 10.1038/s41586-020-2349-y.
  4. GSK COVID Contact Center. [electronic resource]. URL: https://www.sot_rovimab.com/hcp/dosing-and-administration.
  5. ClinicalTrials.gov is a database The National Library of Medicine (NLM) at the National Institutes of Health (NIH) [electronic resource]. URL: https://clinicaltrials.gov/ct2/results?cond&intr=VIR-7831+OR+Sotrovimab+OR+GSK4182136.
  6. Anil Gupta M.D., Gonzalez-Rojas Y., et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021;27. doi: 10.1056/NEJMoa2107934.
  7. Laurini E., Marson D., Aulic S., et al. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. Sci Rep. 2021;11(1):20274. doi: 10.1038/s41598-021-99827-3.
  8. Gottlieb R.L., Nirula A., Chen P., et al. Effect of Bamlanivimab as Monotherapy or in Combination WithEtesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(7):632-44.
  9. Huai-rong Xiang, Bei He, Yun Li, et al. The efficacy and safety of bamlanivimab treatment against COVID-19: A meta-analysis medRxiv. 2021.08.24.21262580. doi: 10.1101/2021.08.24.21262580.
  10. Choudhary M.C., Kara W. Chew et al. Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy, for the ACTIV-2/A5401 Study Team medRxiv 2021.09.03.21263105. Doi: /10.1101/2021.09.03.21263105.
  11. Sabin A.P,. Richmond C.S., Kenny PA. Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient. medRxiv. 2021.10.02.21264415. doi: 10.1101/2021.10.02.21264415.
  12. Bierle D.M., Ganesh R., Tulledge-Scheitel S., et al. Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities Razonable. medRxiv. 2021.10.19.21265222. doi: 10.1101/2021.10.19.21265222.
  13. FDA News events. Coronavirus (COVID-19) Update: FDA Authorizes Additional Monoclonal Antibody for Treatment of COVID-19. Published: May 26, 2021. URL: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-monoclonal-antibody-treatment-covid-19
  14. EMA news. EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19. Published: 21/05/2020. URL: https://www.ema.europa.eu/en/news/ema-issues-advice-use-sotrovimab-vir-7831-treating-covid-19
  15. The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for therapeutic goods. News & public notices, Published: 20.08.2021. TGA provisionally approves GlaxoSmithKline's COVID-19 treatment: sotrovimab (XEVUDY). URL: https://www.tga.gov.au/media-release/tga-provisionally-approves-glaxosmithklines-covid-19-treatment-sotro vimab-xevudy
  16. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information [electronic resource]. URL: https://www.fda.gov/media/145801/download EMA issues advice on use of antibody combination (bamlanivima/etesevimab /URL: https://www.ema.europa.eu/en/news/ema-issues-advice-use-antibody-combination-bamlanivimab-etesevimab
  17. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information [electronic resource]:. URL: https://www.fda.gov/media/145802/download
  18. FDA, Coronavirus Disease 2019 (COVID-19) EUA Information [electronic resource]. URL: https://www.fda.gov/media/149534/download

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2021

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies